Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives.
Y, G., K, L., W, L., M, W., F, L., M, L., J, P., M, Y., L, Z., & H, Z. (2026). Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives.. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology. https://doi.org/10.1002/wnan.70071
Y G, K L, W L, M W, F L, M L, et al. Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives.. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology. 2026; doi: 10.1002/wnan.70071
Y G, K L, W L, et al. Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives.[J]. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology. 2026. DOI: 10.1002/wnan.70071.
@article{y2026,
author = {Guo Y and Lu K and Luo W and Wei M and Li F and Li M and Peng J and Yang M and Zhao L and Zhang H},
title = {Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives.},
journal = {Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology},
year = {2026},
doi = {10.1002/wnan.70071},
note = {PMID: 42521280},
}
TY - JOUR AU - Guo Y AU - Lu K AU - Luo W AU - Wei M AU - Li F AU - Li M AU - Peng J AU - Yang M AU - Zhao L AU - Zhang H TI - Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives. T2 - Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology PY - 2026 DO - 10.1002/wnan.70071 AN - PMID:42521280 ER -
Glioblastoma (GBM) remains one of the most aggressive primary brain tumors, with poor prognosis, high recurrence, and limited therapeutic options. Although substantial progress has been made in drug development, effective clinical translation is still constrained by inefficient delivery across the blood brain barrier (BBB) and blood brain tumor barrier (BBTB), insufficient tumor accumulation, intratumoral heterogeneity, acquired therapeutic resistance, and dose limiting systemic toxicity. Nanomedicine offers a promising strategy to address these barriers through tunable physicochemical properties, flexible surface functionalization, improved pharmacokinetics, and controllable drug release. In this review, we systematically summarize recent advances in nanomedicine enabled GBM therapy from four interrelated perspectives: the optimization of nanomaterial properties, the development of goal-oriented targeting strategies, the rationalization of delivery routes, and the engineering of smart stimuli-responsive nano-systems. Rather than only cataloguing representative nanoplatforms, we emphasize how material parameters, biological targeting mechanisms, delivery routes, and release behaviors are mechanistically linked to BBB or BBTB penetration, tumor accumulation, therapeutic efficacy, and translational feasibility. Importantly, we also incorporate a key failure case analysis of representative clinical and preclinical studies, highlighting why promising nanotherapeutic concepts may fail because of inadequate intratumoral distribution, insufficient survival benefit, poor patient selection, manufacturing complexity, safety concerns, or impractical trial design. By integrating delivery mechanisms, cross platform comparison, translational barriers, and future optimization principles, this review provides a critical and forward looking framework for the rational design of precise, effective, and clinically translatable nanomedicine strategies for GBM treatment.